GenVec picks up the pieces after trial halt; Merck preps Ebola vaccine for submission;

@FierceBiotech: Top 10 mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accent. Report | Follow @FierceBiotech

@JohnCFierce: Seeing some silly reactions to $ZFGN this a.m. No trial that ends in a complete hold is a "success," and efficacy data won't lift that hold. | Follow @JohnCFierce

@DamianFierce: Index Ventures' official Dick Costolo announcement is a link to his tweets of screenshots from his notes app. Website | Follow @DamianFierce

> GenVec ($GNVC) is working to move on after a safety issue led partner Novartis ($NVS) to halt clinical development of its lead asset, a treatment for hearing loss. More

> Merck ($MRK) is planning to file its Ebola vaccine for global approvals next year. Story

> U.K. biotech Immunocore started a Phase Ib/II trial combining its immuno-oncology candidate IMCgp100 with durvalumab and tremelimumab, two cancer therapies in development by AstraZeneca ($AZN). News

Medical Device News

@FierceMedDev: IBM bets its future on machine learning and Watson Health. More | Follow @FierceMedDev

@VarunSaxena2: Interesting article in @TheEconomist. Which lifesci hub do you think is no. 1? Poll | Follow @VarunSaxena2

@EmilyWFierce: Roche blindsided by off-label Avastin fallout in #India. Story | Follow @EmilyWFierce

> Spanish researchers prototype robotic arm for shoulder rehabilitation. More

> Randomized trial finds smartphone-enabled patient monitors don't decrease healthcare utilization. Article

Pharma News

@FiercePharma: Roche blindsided by off-label Avastin fallout in India. More | Follow @FiercePharma

@CarlyHFierce: ICYMI: Big question for Pfizer: Will Enbrel's EU biosim bring on the pain? Story | Follow @CarlyHFierce

> Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals. More

> NHS watchdog takes issue with Pfizer exec's new role on foundation trust's board. News

> Pfizer looks to Russian partnership to produce some of its meds there, report says. Story

Biotech Research News

> New study offers researchers a guide to making next-gen TB drugs. More

> Allergan highlights preclinical evidence of cognitive safety for fast-acting depression drug. News

> Scripps team spots a new mechanism that drives Celgene's ozanimod, potential rivals. Story

> Columbia U. team refines replacement cells for injured hearts. Article

> Study presents a fresh opportunity for early ovarian cancer diagnosis. Report

Pharma Marketing News

> Glass half empty? Pharma staffers about as content as average Americans, survey finds. Story

> Pharma's December TV spending sags; Pfizer and BMS' Eliquis rises to top. News

> Takeda's U.K. unit brings sales force in-house to boost efforts in oncology, IBD. Report

> Merck & Co. sues Merck KGaA over naming rights in transatlantic tug-of-war. Article

> Minds + Assembly jumps off big pharma agencies, aims for 'breakthrough' work with Orexo. More

Vaccines News

> Merck to submit Ebola vaccine for regulatory approval in 2017. Story

> FDA expands indication for GSK's Hib vaccine, Hiberix. News

> Dengue vaccine developed at NIH enters PhIII in Brazil. More

> Baltimore's Profectus BioSciences starts PhI trial of Ebola vaccine. Report

> Sanofi working with health authorities on dengue vaccine strategies. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.